A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Clinical Pharmacology and Therapeutics"
DOI: 10.5414/cp203343
Abstract: Objective: Ertugliflozin is approved in the US and European Union as a stand-alone product for adults with type 2 diabetes mellitus as once daily (QD) dosing. The approved fixed-dose combination (FDC) of ertugliflozin and immediate-release… read more here.
Keywords: twice daily; daily dosing; healthy subjects; bid ... See more keywords